For anyone in Lepea searching for CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. What this means for Lepea researchers is that your location matters far less than your ability to assess COA data — and those quality checks are available to every researcher. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. This guide gives Lepea researchers the framework to assess vendor quality rigorously and source high-purity CJC-1295 with confidence.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Lepea comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor share complete COA data without being asked? Vendors who do are signalling genuine quality commitment. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. The combination of community consensus and independent COA review is the gold standard for CJC-1295 sourcing — community feedback surfaces systemic problems invisible in one transaction, and vice versa. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order CJC-1295 — ships to Lepea
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with sterile bacteriostatic water. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger severe inflammatory responses at minute levels, and no pricing advantage justifies skipping this verification. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
